{"id":36816,"date":"2018-11-01T17:35:00","date_gmt":"2018-11-01T16:35:00","guid":{"rendered":"https:\/\/supazena.ovh\/c\/etap\/?post_type=ressource&p=36631"},"modified":"2026-04-15T22:48:46","modified_gmt":"2026-04-15T20:48:46","slug":"newsletter-3b","status":"publish","type":"ressource","link":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/","title":{"rendered":"Newsletter #3"},"content":{"rendered":"\n
\"\"\/<\/figure>\n\n\n\n

New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis<\/h3>\n\n\n\n

ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced psoriasis model. The output of these studies showed that TEM1657 brings remarkable effects on psoriasis:<\/p>\n\n\n\n

\u2022 Higher efficacy compared to the reference molecule<\/p>\n\n\n\n

\u2022 No side effects<\/p>\n\n\n\n

\u2022 Oral administration, which is new for the psoriasis treatment<\/p>\n\n\n\n

The French biotech company \u201cTemesis\u201d, subsidiary of Plant Advanced Technologies, recently published a new press release to announce these new promising preclinical results on psoriasis with TEM1657.<\/p>\n\n\n\n

Link to the press release<\/a><\/p>\n\n\n\n

The results of these new ETAP-Lab studies, together with in vitro<\/em> studies, have been presented by TEMISIS in a poster at the International Investigative Dermatology 2018 in Orlando (Florida, U.S.A.) last May.<\/p>\n\n\n\n

The mechanism of action of TEM1657 uses the Th17-dependant pathway which does not only give hope to psoriasis treatment but also to widespread inflammatory conditions such as Crohn\u2019s disease or ulcerative colitis.<\/p>\n\n\n\n

Link to the poster<\/a><\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

Figure 1: In vitro efficacy profile: microscopic view of the cells <\/strong><\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

Figure 2: In vivo efficacy profile: PASI scoring <\/strong><\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

Figure 3: In vivo efficacy profile: Skin shape and histology <\/strong><\/p>\n\n\n\n

\n\n\n\n

Flash News<\/em><\/h1>\n\n\n\n

Benefits of a probiotic mixture
on skin inflammation<\/strong><\/h3>\n\n\n\n

S. Holowacz, I. Guinobert, A. Guilbot, S.Hidalgo, J. F. Bisson
Published in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry,
2018 August 13th<\/em><\/p>\n\n\n\n

There is a growing interest in the effects of probiotics for the prevention and treatment of skin diseases due to their immunomodulatory and anti-inflammatory properties.<\/p>\n\n\n\n

In collaboration with PiLeJe Group specialized in Micronutrition and Phytotherapy, ETAP-Lab has assessed a mixture of five bacterial strains in the prevention of chronic skin inflammation in mice.<\/p>\n\n\n\n

These very interesting results have shown that the probiotic mixture tested considerably limited the induced chronic skin inflammation at both macroscopic and microscopic levels. Therefore, its use could be valuable for dermatological disorders such as atopic dermatitis and psoriasis by preserving skin integrity and homeostasis.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

Figure 1: Evolution of the macroscopic score of chronic skin inflammation during the treatment period and representative images of the back of one mouse of each treatment group (a: Negative control; b: Positive control; c: Probiotic group)<\/strong><\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

Figure 2: Haematoxylin and eosin-stained dorsal skin section of a mouse represen-tative of each treatment group<\/strong><\/p>\n\n\n\n

Link to the article<\/a><\/p>\n\n\n\n

\n\n\n\n
ETAP-Lab<\/em> has strong experience in the field of dermatology research by developing a wide portfolio of original in vivo models.<\/h5>\n\n\n\n
With total transparency, our expertise and know-how include:
– Respecting chronobiology and animal well-being
– Considering chronopharmacology during treatments
– Evaluating animal behavior to confirm beneficial\/ adverse effects of treatments<\/h5>\n","protected":false},"excerpt":{"rendered":"

Discover Newsletter #3: New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced\u2026<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"categorie-de-ressource":[238],"marque-de-ressource":[],"class_list":["post-36816","ressource","type-ressource","status-publish","hentry","categorie-de-ressource-technical-notes"],"acf":[],"yoast_head":"\nNewsletter #3 - ETAP-LAB<\/title>\n<meta name=\"description\" content=\"Discover Newsletter #3: New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Newsletter #3 - ETAP-LAB\" \/>\n<meta property=\"og:description\" content=\"Discover Newsletter #3: New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/\" \/>\n<meta property=\"og:site_name\" content=\"ETAP-LAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T20:48:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/gallery.mailchimp.com\/c834cbe69787d0473a8df769d\/images\/948310de-9eef-43ec-87d6-8f17c5740df2.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/\",\"name\":\"Newsletter #3 - ETAP-LAB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/gallery.mailchimp.com\\\/c834cbe69787d0473a8df769d\\\/images\\\/948310de-9eef-43ec-87d6-8f17c5740df2.png\",\"datePublished\":\"2018-11-01T16:35:00+00:00\",\"dateModified\":\"2026-04-15T20:48:46+00:00\",\"description\":\"Discover Newsletter #3: New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/#primaryimage\",\"url\":\"https:\\\/\\\/gallery.mailchimp.com\\\/c834cbe69787d0473a8df769d\\\/images\\\/948310de-9eef-43ec-87d6-8f17c5740df2.png\",\"contentUrl\":\"https:\\\/\\\/gallery.mailchimp.com\\\/c834cbe69787d0473a8df769d\\\/images\\\/948310de-9eef-43ec-87d6-8f17c5740df2.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/newsletter-3b\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ressources\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressources\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Technical notes\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/categorie-de-ressource\\\/technical-notes\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Newsletter #3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"name\":\"Etap Lab\",\"description\":\"CRO Services\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\",\"name\":\"Etap Lab\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"width\":550,\"height\":550,\"caption\":\"Etap Lab\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/etap-lab\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Newsletter #3 - ETAP-LAB","description":"Discover Newsletter #3: New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/","og_locale":"en_US","og_type":"article","og_title":"Newsletter #3 - ETAP-LAB","og_description":"Discover Newsletter #3: New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced\u2026","og_url":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/","og_site_name":"ETAP-LAB","article_modified_time":"2026-04-15T20:48:46+00:00","og_image":[{"url":"https:\/\/gallery.mailchimp.com\/c834cbe69787d0473a8df769d\/images\/948310de-9eef-43ec-87d6-8f17c5740df2.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/","url":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/","name":"Newsletter #3 - ETAP-LAB","isPartOf":{"@id":"https:\/\/www.etap-lab.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/#primaryimage"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/#primaryimage"},"thumbnailUrl":"https:\/\/gallery.mailchimp.com\/c834cbe69787d0473a8df769d\/images\/948310de-9eef-43ec-87d6-8f17c5740df2.png","datePublished":"2018-11-01T16:35:00+00:00","dateModified":"2026-04-15T20:48:46+00:00","description":"Discover Newsletter #3: New ETAP-Lab studies on TEMISIS\u2019 drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced\u2026","breadcrumb":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/#primaryimage","url":"https:\/\/gallery.mailchimp.com\/c834cbe69787d0473a8df769d\/images\/948310de-9eef-43ec-87d6-8f17c5740df2.png","contentUrl":"https:\/\/gallery.mailchimp.com\/c834cbe69787d0473a8df769d\/images\/948310de-9eef-43ec-87d6-8f17c5740df2.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/newsletter-3b\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.etap-lab.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ressources","item":"https:\/\/www.etap-lab.com\/en\/ressources\/"},{"@type":"ListItem","position":3,"name":"Technical notes","item":"https:\/\/www.etap-lab.com\/en\/categorie-de-ressource\/technical-notes\/"},{"@type":"ListItem","position":4,"name":"Newsletter #3"}]},{"@type":"WebSite","@id":"https:\/\/www.etap-lab.com\/en\/#website","url":"https:\/\/www.etap-lab.com\/en\/","name":"Etap Lab","description":"CRO Services","publisher":{"@id":"https:\/\/www.etap-lab.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.etap-lab.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.etap-lab.com\/en\/#organization","name":"Etap Lab","url":"https:\/\/www.etap-lab.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","width":550,"height":550,"caption":"Etap Lab"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/etap-lab\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/ressource\/36816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/ressource"}],"about":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/types\/ressource"}],"wp:attachment":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/media?parent=36816"}],"wp:term":[{"taxonomy":"categorie-de-ressource","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/categorie-de-ressource?post=36816"},{"taxonomy":"marque-de-ressource","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/marque-de-ressource?post=36816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}